Skip to main content
. 2016 Jan 12;17(1):89. doi: 10.3390/ijms17010089

Figure 4.

Figure 4

Survivin silencing decreases the malignant phenotype of RasG12V-ΙκΒαΜ-derived tumors. (A) Hematoxilin and Eosin staining of survivin siRNA-treated RasG12V-ΙκΒαΜ-derived tumors; (B) Mitotic Index representing the number of cells undergoing mitosis over total cells. Scale bars = 200 µm; (C) HIF1α staining in survivin siRNA transfected NoLacZ or RasG12V-ΙκΒαΜ tumors evaluated by immunofluorescence; (D) VEGF staining in survivin siRNA transfected NoLacZ or RasG12V-ΙκΒαΜ tumors evaluated by immunofluorescence; (E) CD51 staining in survivin siRNA transfected NoLacZ or RasG12V-ΙκΒαΜ tumors evaluated by immunofluoresce; (F) HIF1α (upper panel) and CD51 (lower panel) positive cell count assessed by ImageJ software (* 0.01 < p < 0.05; ** p < 0.01). Scale bars = 200 µm.